A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
NCT04998812
Recruiting
This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
11/29/2023
Locations: University of California San Francisco, San Francisco, California +15 locations
Conditions: Multiple Sclerosis, Clinically Isolated Syndrome
Register for Updates
The Neural Mechanisms of Split-belt Treadmill Adaptation in People With Multiple Sclerosis
NCT05878873
Recruiting
Majority of people with multiple sclerosis experience difficulty with balance and mobility, leading to an increased risk of falls. The goal of this clinical trial is to learn about brain activity during walking adaptation in people with multiple sclerosis. Also, this clinical trial will test a form of nerve stimulation to see if it can improve walking performance. The main questions it aims to answer are: What areas of the brain are the most active during walking adaptation? Can nerve stimulat... Read More
Gender:
All
Ages:
Between 18 years and 86 years
Trial Updated:
11/28/2023
Locations: The Sensorimotor Neuroimaging Laboratory, Fort Collins, Colorado
Conditions: Multiple Sclerosis
Register for Updates
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999
Recruiting
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks in participants with PPMS, in comparison to the approved 600 mg dose of ocrelizumab.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2023
Locations: Alabama Neurology Associates, Homewood, Alabama +211 locations
Conditions: Multiple Sclerosis
Register for Updates
Obesity and Pediatric Multiple Sclerosis
NCT04593082
Recruiting
Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on pediatric MS disease expression and course is unknown. This study will evaluate the relationship between obesity, obesity-derived inflammatory mediators, and imaging metrics of MS severity in children. Understanding how childhood obesity contributes to MS severity/progression may yield fundamental i... Read More
Gender:
All
Ages:
Between 10 years and 20 years
Trial Updated:
11/27/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania +1 locations
Conditions: Multiple Sclerosis
Register for Updates
Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue
NCT05848323
Recruiting
This prospective case series will use mixed methods to examine the feasibility, acceptability, and initial effects of three telehealth cognitive behavioral therapy components (relaxation training, behavioral activation, cognitive therapy) for fatigue in people with multiple sclerosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Multiple Sclerosis Center at UW Medical Center - Northwest, Seattle, Washington
Conditions: Multiple Sclerosis, Fatigue
Register for Updates
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
NCT05853835
Recruiting
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single Oral Dose of LPX-TI641.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
11/27/2023
Locations: AXIS Clinicals, Dilworth, Minnesota +1 locations
Conditions: Autoimmune Diseases, Multiple Sclerosis
Register for Updates
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
NCT04998851
Recruiting
This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
11/23/2023
Locations: University of California San Francisco, San Francisco, California +9 locations
Conditions: Multiple Sclerosis, Clinically Isolated Syndrome
Register for Updates
A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis
NCT05865405
Recruiting
The researchers want to find out if an electronic application called MS CATCH can enhance patients' and doctors' experiences during and in between clinical visits. MS CATCH is a smartphone-based tool which allows patients to enter their mood related symptoms at regular intervals, which is then available to their Neurologist in their electronic medical record. The neurologist is also able to view additional information from their medical record, and receives alerts for changes reported by the pat... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/21/2023
Locations: Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, MS, Depression
Register for Updates
Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis
NCT05888727
Recruiting
The goal of this randomized controlled clinical trial is to examine the feasibility and initial efficacy of undertaking and delivering a novel, stakeholder-informed exercise training program for wheelchair users with multiple sclerosis. The main questions it aims to answer are: Is the study feasible as measured by participant recruitment (24 participants total), retention (80%), and safety (adverse events)? Is the study acceptable as measured by participant satisfaction and perceptions using an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Multiple Sclerosis
Register for Updates
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
NCT04075266
Recruiting
This 2-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
11/17/2023
Locations: Loma Linda University health, Loma Linda, California +23 locations
Conditions: Multiple Sclerosis
Register for Updates
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
NCT00794352
Recruiting
Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least... Read More
Gender:
All
Ages:
99 years and below
Trial Updated:
11/15/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Central Nervous System Disease, Multiple Sclerosis
Register for Updates
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
NCT03109288
Recruiting
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to. Objective: To see if signs of inflammation in CSF help predict a person s response to different drugs. Eligibility: People ages 18 and older who: Are in protocol 09-I-0032... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates